Literature DB >> 8548046

Effects of growth hormone and insulin-like growth factor I on the immune system.

C J Auernhammer1, C J Strasburger.   

Abstract

Growth hormone-releasing hormone (GHRH), growth hormone (GH), prolactin (PRL) and insulin-like growth factor I (IGF-I) are synthesized and secreted by various immunocompetent cells. In addition, GHRH, GH, PRL and IGF-I receptors are expressed on immune cells. Growth hormone, PRL and IGF-I stimulate the proliferation of immunocompetent cells and modulate humoral and cellular immune functions, i.e. immunoglobuline secretion of B cells, thymulin secretion of thymic epithelial cells, natural killer cell activity, phagocytosis, oxidative burst and killing capacity of neutrophils and macrophages. No clinically significant cellular or humoral immunodeficiency has been found in GH-deficient patients. However, several immunological parameters and functions are altered in GH-deficient patients when compared to normal controls. The data available to date indicate that endocrine and pleiotropic para- and autocrine mechanisms of action are involved in a neuropeptide immune network, including GH, PRL and IGF-I as modulators of immune function.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8548046     DOI: 10.1530/eje.0.1330635

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  19 in total

Review 1.  Molecular heterogeneity of human GH: from basic research to clinical implications.

Authors:  C L Boguszewski
Journal:  J Endocrinol Invest       Date:  2003-03       Impact factor: 4.256

Review 2.  Immune-based therapies: an adjunct to antiretroviral treatment.

Authors:  Jeffrey M Jacobson
Journal:  Curr HIV/AIDS Rep       Date:  2005-06       Impact factor: 5.071

Review 3.  Growth hormone. A paracrine growth factor?

Authors:  S Harvey; K L Hull
Journal:  Endocrine       Date:  1997-12       Impact factor: 3.633

4.  Infectious diseases and immunological responses in adult subjects with lifetime untreated, congenital GH deficiency.

Authors:  Viviane C Campos; Mônica R Barrios; Roberto Salvatori; Roque Pacheco de Almeida; Enaldo V de Melo; Ana C S Nascimento; Amélia Ribeiro de Jesus; Manuel H Aguiar-Oliveira
Journal:  Endocrine       Date:  2016-08-03       Impact factor: 3.633

5.  Growth hormone interacts with the Marek's disease virus SORF2 protein and is associated with disease resistance in chicken.

Authors:  H C Liu; H J Kung; J E Fulton; R W Morgan; H H Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-24       Impact factor: 11.205

Review 6.  [Malnutrition and osteoporosis].

Authors:  R Rizzoli; J P Bonjour
Journal:  Z Gerontol Geriatr       Date:  1999-07       Impact factor: 1.281

7.  Assessment of immune function after short-term administration of recombinant human growth hormone in healthy young males.

Authors:  S B Ramos; E W Brenu; R Christy; B Gray; L McNaughton; L Tajouri; M Van Driel; S M Marshall-Gradisnik
Journal:  Eur J Appl Physiol       Date:  2010-12-08       Impact factor: 3.078

8.  HPA and SAS responses to increasing core temperature during uncompensable exertional heat stress in trained and untrained males.

Authors:  Heather E Wright; Glen A Selkirk; Tom M McLellan
Journal:  Eur J Appl Physiol       Date:  2009-12-06       Impact factor: 3.078

9.  Altered time structure of neuro-endocrine-immune system function in lung cancer patients.

Authors:  Gianluigi Mazzoccoli; Gianluigi Vendemiale; Angelo De Cata; Stefano Carughi; Roberto Tarquini
Journal:  BMC Cancer       Date:  2010-06-21       Impact factor: 4.430

10.  Insulin resistance, metabolic syndrome and chronic low grade inflammation in Sheehan's syndrome on standard replacement therapy: a case control study.

Authors:  Manzoor Ahmad Bhat; Bashir Ahmad Laway; Zaffar Amin Shah; Arshad Iqbal Wani; Idrees Mubarik
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.